Status:
UNKNOWN
Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions
Lead Sponsor:
Ospedale Santa Croce-Carle Cuneo
Collaborating Sponsors:
Consorzio Mario Negri Sud
Fondazione Italiana Linfomi - ETS
Conditions:
Hodgkin's Lymphoma
Eligibility:
All Genders
18-60 years
Brief Summary
To assess specificity and overall accuracy of interim dual-point acquisition PET in predicting treatment outcome. The study is aimed at assessing the specificity of interim dual-point PET performed a...
Detailed Description
The proposed study is an non-interventional survey of a cohort of patients in whom interim PET scan is performed only for prognostic aims. PET with 18F-FDG is a standard staging procedure for most ly...
Eligibility Criteria
Inclusion
- Hodgkin lymphoma diagnosis according all the WHO classification subtype but lymphocyte predominance.
- Age 18 - 60 years old
- stage IA- IIA (by FDG-PET scan)
- Presence of bulky tumour (either in Mediastinum or other site)
- Treatment with ABVD x 4 (early stage)
- Consolidation Radiotherapy on bulky lesion
- Signed the Informed consent form
Exclusion
- Diabetes mellitus uncompensated
- Lymphocyte predominance histology
- Pregnancy or lactation
- Implanted biomedical devices (for DW-MRI sub study)
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2017
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01399931
Start Date
January 1 2012
End Date
January 1 2017
Last Update
October 19 2015
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Ospedale Santi Antonio E Biagio E Cesare Arrigo
Alessandria, AL, Italy, 15100
2
Azienda Sanitaria Ospedaliera S. Croce E Carle
Cuneo, Cuneo, Italy, 12100
3
Azienda Ospedaliera Universitaria S. Martino
Genova, GE, Italy, 16132
4
Azienda Ospedaliera S. Gerardo
Monza, MB, Italy, 20900